Partnering

Advancing innovative work with a shared commitment to reach patients

Partners Changing the World

Our partners are advancing the development of next-generation gene therapies with the goal of addressing unmet patient needs. Cirsium supports their progress with AAV manufacturing expertise that moves promising programs forward.

We’re proud to work across the gene therapy field. Public partners include:

Who We Work With

AAV Gene Therapy Developers

Organizations advancing AAV-based therapies for serious, rare, and underserved diseases. Access manufacturing expertise and production capacity that supports programs from early research through development.

Academic Researches

Research teams working to transform scientific discoveries into therapeutic opportunities. Generate research-grade AAV material for proof-of-concept studies, translational research, and early-stage program development.

Patient Advocacy Groups

Organizations championing the needs of patients and families affected by rare and complex diseases. Accelerate therapeutic development through program development.

Technology Innovators

Organizations advancing rare and complex disease research through innovative technologies, platforms, and data-driven solutions.

Support That Grows With Your Program

As your program progresses, so do the demands on manufacturing.

Our platform is designed to seamlessly support this progression, enabling everything from small research lots to larger pre-IND and clinical-scale production, all within a unified, scalable workflow.

Strategic Networks Strengthening the AAV Community

Beyond commercial collaborations, we actively participate in the industry ecosystems that fuel scientific discovery to unlock the full potential of gene therapies.

Moving breakthrough science toward real-world impact?

Whether you’re advancing an AAV program, exploring plant-made biologics, developing enabling technologies, or supporting patients through advocacy and research, we’re always open to conversations.